Judith Currie, NP
Internal Medicine · Fayetteville, GANPI 1134784481
Payments from drug & device makers
Across 250 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$973
- Novo Nordisk$616
- AstraZeneca$553
- GSK$491
- AbbVie$350
- Amgen$268
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,108100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 55 | $973 |
| Novo Nordisk | 36 | $616 |
| AstraZeneca | 17 | $553 |
| GSK | 19 | $491 |
| AbbVie | 21 | $350 |
| Amgen | 10 | $268 |
| Johnson & Johnson | 14 | $261 |
| Boehringer Ingelheim | 12 | $213 |
| Otsuka America Pharmaceutical, Inc. | 7 | $152 |
| Pfizer | 6 | $129 |
| Astellas Pharma US Inc | 5 | $109 |
| Exact Sciences | 6 | $107 |
| Sanofi-aventis U.S. LLC | 5 | $85 |
| Novartis | 4 | $84 |
| Dexcom, Inc. | 4 | $73 |
| Gilead | 2 | $69 |
| Insulet Corporation | 3 | $67 |
| Ironwood Pharmaceuticals, Inc | 3 | $64 |
| Xeris Pharmaceuticals, Inc. | 3 | $60 |
| Baxter Healthcare | 1 | $56 |
| Bayer | 2 | $41 |
| Medtronic | 1 | $37 |
| Merck | 2 | $33 |
| Nevro Corp. | 1 | $26 |
| Abbott | 1 | $24 |
| Boston Scientific | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Corium, LLC | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Mylan Specialty L.p. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Global Blood Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$250
- TRELEGY ELLIPTA$125
- Repatha$120
- MOUNJARO$103
How this compares
$5,120 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 98 | $129,941 |
| JardianceEmpagliflozin | 61 | $71,006 |
| MounjaroTirzepatide | 61 | $69,333 |
| EliquisApixaban | 48 | $53,279 |
| TrulicityDulaglutide | 27 | $36,974 |
| FarxigaDapagliflozin Propanediol | 44 | $33,566 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $31,024 |
| XareltoRivaroxaban | 15 | $23,115 |
| JanuviaSitagliptin Phosphate | 16 | $22,845 |
| MyrbetriqMirabegron | 13 | $19,215 |
| Memantine Hcl ErMemantine Hcl | 32 | $4,845 |
| Atorvastatin Calcium | 517 | $4,261 |
| Rosuvastatin Calcium | 422 | $3,723 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 11 | $2,924 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $2,450 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $616 | $129,94198 claims |
| Lilly USA, LLCMounjaro, Trulicity | $973 | $106,30788 claims |
| Boehringer IngelheimJardiance | $213 | $71,00661 claims |
| PfizerEliquis | $129 | $53,27948 claims |
| AstraZenecaFarxiga | $553 | $33,56644 claims |
| GSKTrelegy Ellipta | $491 | $31,02424 claims |
| Johnson & JohnsonXarelto | $261 | $23,11515 claims |
| MerckJanuvia | $33 | $22,84516 claims |
| Astellas Pharma US IncMyrbetriq | $109 | $19,21513 claims |
| AbbVieSynthroid | $350 | $2,24734 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Fayetteville
- Charlotte Grayson-MathisFayetteville$9.6M
- Frank ColeFayetteville$673K
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.